The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Factors that Raise the Risk of Hepatitis C Relapse

Back to News Homepage

Next

The Hepatitis A Virus Loves Summertime

A Trio of New Hepatitis C Drugs Being Tested

July 13, 2011

Print this page

Hoping to simplify and improve Hepatitis C treatment, Achillion is testing several proprietary compounds – including the recent start of a Phase 1 trial to assess ACH-2684.

Achillion Pharmaceuticals Inc. (ACHN) Begins Dosing for Hepatitis C Treatment, Prepares for Clinical Milestones

By QualityStocks | July 12, 2011

Achillion Pharmaceuticals Inc., focused on developing treatments for infectious disease, today announced it has begun dosing in a phase 1 clinical trial of ACH-2684 for the treatment of chronic hepatitis C virus (HCV) infection.

The study is a randomized, double-blind, placebo-controlled trial designed to determine the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2684, and will include up to 78 healthy volunteers and up to 40 HCV-infected patients.

“This first-in-human clinical trial will be instrumental in establishing the safety profile of ACH-2684 in humans,” Elizabeth A. Olek, D.O., vice president and chief medical officer of Achillion stated in the press release. “It will also provide Achillion with important preliminary efficacy data against HCV genotypes 1 and 3, and help us to select doses for subsequent clinical development.”

Continue reading this entire article:
http://hken.ibtimes.com/articles/177911/20110712/achillion-pharmaceuticals-inc-achn-begins-dosing-for-hepatitistreatment-prepares-for-clinical-milest.htm

No Comments - be the first!
Share
Share

Previous

Factors that Raise the Risk of Hepatitis C Relapse

Back to News Homepage

Next

The Hepatitis A Virus Loves Summertime

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.